trial

Influence of rTMS on Symptoms and Cognitive Function in Patients With Psychiatric Disorders

NCTId NCT04055181
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 800 (actual)
Sponsored by Beijing HuiLongGuan Hospital
Primary completion 2019-12-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
800 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-12-01
Primary completion
2019-12-30
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
rTMS in schizophrenia patientsrTMS in major depressive disorders patients

Sponsors

Beijing HuiLongGuan HospitalLead Sponsor

Investigators

1
Xiang Y Zhang, MD,PhDPrincipal Investigator

Sites

6 total
Chaohu, ChinaZhongshan, ChinaWuhan, ChinaGanzhou, ChinaNing’an, ChinaXi’an, China

Facts & assertions

4 sourced
Enrollment
800
Phase
NA
Primary Completion Date
2019-12-30
Status
COMPLETED
relationships
The graph out of here
drug
rTMS in schizophrenia patients
drug
rTMS in major depressive disorders patients
drug
lead_sponsor
Beijing HuiLongGuan Hospital
company
indication
Smoking
indication
Major Depressive Disorder
indication
Depressive Disorder, Major
indication
investigator
Xiang Y Zhang, MD,PhD
person